Evaxion Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Evaxion Biotech AS
EVAX Stock  USD 1.66  0.09  5.73%   
Evaxion Biotech financial statements provide useful quarterly and yearly information to potential Evaxion Biotech AS investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Evaxion Biotech financial statements helps investors assess Evaxion Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Evaxion Biotech's valuation are summarized below:
Market Capitalization
13.3 M
Enterprise Value Revenue
3.7128
Revenue
3.3 M
Earnings Share
(2.80)
Revenue Per Share
0.713
We have found one hundred twenty available fundamental signals for Evaxion Biotech AS, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Evaxion Biotech AS prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 20.5 M in 2024. Enterprise Value is likely to drop to about 26.3 M in 2024
Check Evaxion Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evaxion Biotech's main balance sheet or income statement drivers, such as Interest Income of 1.4 M, Depreciation And Amortization of 330.1 K or Interest Expense of 1 M, as well as many indicators such as Price To Sales Ratio of 206, Dividend Yield of 0.0 or Days Sales Outstanding of 4.3 K. Evaxion financial statements analysis is a perfect complement when working with Evaxion Biotech Valuation or Volatility modules.
  
Check out the analysis of Evaxion Biotech Correlation against competitors.

Evaxion Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Short and Long Term Debt Total11.4 M10.9 M2.5 M
Slightly volatile
Other Current Liabilities4.1 M3.9 M973.6 K
Slightly volatile
Total Current Liabilities5 M7.1 M2.6 M
Slightly volatile
Property Plant And Equipment Net2.4 M4.3 M1.3 M
Slightly volatile
Accounts Payable1.9 M2.7 M964 K
Slightly volatile
Cash5.3 M5.6 M5.5 M
Slightly volatile
Non Current Assets Total3.4 M4.5 M1.8 M
Slightly volatile
Cash And Short Term Investments5.3 M5.6 M5.5 M
Slightly volatile
Net Receivables1.1 M1.1 M1.7 M
Slightly volatile
Common Stock Shares Outstanding3.2 M2.7 M9.7 M
Slightly volatile
Non Current Liabilities Total11.1 M10.5 M2.6 M
Slightly volatile
Capital Lease Obligations1.1 M2.2 M639.8 K
Slightly volatile
Other Current Assets2.3 M1.7 M1.2 M
Slightly volatile
Total Liabilities18.5 M17.6 M5.1 M
Slightly volatile
Net Invested Capital3.7 M3.9 M6.8 M
Slightly volatile
Total Current Assets13.3 M8.3 M7.8 M
Slightly volatile
Short Term Debt460.8 K485 K738.2 K
Pretty Stable
Common Stock3.6 M5.9 M2.8 M
Slightly volatile
Short and Long Term Debt151.1 K159 K5.2 M
Slightly volatile
Capital Stock3.8 M5.9 M2.8 M
Slightly volatile
Property Plant Equipment6.2 M6 M1.6 M
Slightly volatile
Property Plant And Equipment Gross3.9 M5.5 M1.6 M
Slightly volatile
Intangible Assets77.2 K83.7 K96.5 K
Slightly volatile
Other Liabilities122.4 K137.7 K149.9 K
Slightly volatile
Long Term Debt6.4 M8.5 M2.4 M
Slightly volatile
Current Deferred Revenue1.61.81.96
Slightly volatile
Short Term Investments132148162
Slightly volatile
Non Current Liabilities Other8 K9 K9.8 K
Slightly volatile

Evaxion Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.4 M2.3 M588.1 K
Slightly volatile
Depreciation And Amortization330.1 K615.9 K181.5 K
Slightly volatile
Interest Expense1 M897 K803.2 K
Slightly volatile
Selling General Administrative6.4 M10.4 M3.8 M
Slightly volatile
Other Operating Expenses19.5 M22.3 M11.4 M
Slightly volatile
Research Development13.1 M11.9 M7.6 M
Slightly volatile
Total Operating Expenses19.5 M22.2 M11.4 M
Slightly volatile
Reconciled Depreciation328.2 K615 K180.7 K
Slightly volatile
Cost Of Revenue106112122 K
Pretty Stable
Selling And Marketing Expenses220 K247.5 K269.5 K
Slightly volatile

Evaxion Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation455.1 K479 K1.8 M
Slightly volatile
Begin Period Cash Flow12.6 M13.2 M5.7 M
Slightly volatile
Depreciation328.2 K615 K180.7 K
Slightly volatile
Capital Expenditures82.7 K87 K155.9 K
Slightly volatile
Change To Operating Activities18 K18.9 K368.7 K
Slightly volatile
Issuance Of Capital Stock15.2 M9.2 M7.1 M
Slightly volatile
Total Cash From Financing Activities17.5 M10.7 M12.4 M
Slightly volatile
End Period Cash Flow5.3 M5.6 M9.2 M
Pretty Stable
Change To Netincome870.4 K916.2 K2.1 M
Slightly volatile
Dividends Paid132 K148.5 K161.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio206231252
Slightly volatile
Days Sales Outstanding4.3 K4.8 K5.3 K
Slightly volatile
Stock Based Compensation To Revenue5.255.916.4308
Slightly volatile
Capex To Depreciation0.130.14150.6722
Slightly volatile
EV To Sales263296323
Slightly volatile
Payables Turnover0.00.00.3557
Slightly volatile
Sales General And Administrative To Revenue113128139
Slightly volatile
Research And Ddevelopement To Revenue131147160
Slightly volatile
Capex To Revenue0.951.071.1675
Slightly volatile
Cash Per Share1.942.04244.6939
Pretty Stable
Days Payables Outstanding9.2 M8.8 M1.2 M
Slightly volatile
Income Quality0.620.79960.5413
Slightly volatile
Intangibles To Total Assets0.00250.00270.0068
Slightly volatile
Current Ratio1.121.17876.3179
Slightly volatile
Receivables Turnover0.05430.06110.0665
Slightly volatile
Graham Number33.5117.749521.9829
Slightly volatile
Capex Per Share0.03020.03180.0798
Slightly volatile
Revenue Per Share0.02140.0240.0262
Slightly volatile
Interest Debt Per Share2.173.49183.5066
Slightly volatile
Operating Cycle4.3 K4.8 K5.3 K
Slightly volatile
Days Of Payables Outstanding9.2 M8.8 M1.2 M
Slightly volatile
Ebt Per Ebit1.131.03231.0801
Slightly volatile
Effective Tax Rate0.06490.03450.0904
Slightly volatile
Quick Ratio1.121.17876.4946
Slightly volatile
Net Income Per E B T0.750.96550.8972
Pretty Stable
Cash Ratio0.750.78812.1576
Pretty Stable
Days Of Sales Outstanding4.3 K4.8 K5.3 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.00490.998
Pretty Stable
Fixed Asset Turnover0.01340.01510.0165
Slightly volatile
Price Sales Ratio206231252
Slightly volatile
Asset Turnover0.00450.00510.0056
Slightly volatile
Gross Profit Margin0.80.90.9787
Slightly volatile

Evaxion Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap20.5 M21.6 M145.1 M
Slightly volatile
Enterprise Value26.3 M27.6 M144 M
Slightly volatile

Evaxion Fundamental Market Drivers

Forward Price Earnings3.5714
Cash And Short Term Investments5.6 M

Evaxion Upcoming Events

25th of April 2024
Upcoming Quarterly Report
View
29th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Evaxion Biotech Financial Statements

Evaxion Biotech investors use historical fundamental indicators, such as Evaxion Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Evaxion Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 1.80  1.60 
Total Revenue73 K76.7 K
Cost Of Revenue 112.00  106.40 
Stock Based Compensation To Revenue 5.91  5.25 
Sales General And Administrative To Revenue 127.65  113.47 
Research And Ddevelopement To Revenue 146.91  130.58 
Capex To Revenue 1.07  0.95 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(273.66)(287.34)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Evaxion Stock Analysis

When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY